Scientists at the University of North Carolina have engineered immune cells that can destroy acute myeloid leukemia (AML) while sparing healthy blood tissue, overcoming a key limitation of standard treatments. The research, led by immunologist Gianpietro Dotti and hematologist Paul Armistead, appears in the journal Blood and offers a promising approach for patients battling this deadly disease.
Current immunotherapies for AML often struggle to distinguish between cancerous and normal cells, leading to severe side effects or limited efficacy. The UNC team designed chimeric antigen receptor (CAR) T cells that target a specific antigen present on AML cells but not on healthy hematopoietic stem cells. In preclinical models, these engineered cells eliminated leukemia while preserving normal blood cell production, a significant improvement over existing therapies.
The study represents a step toward more precise cancer treatments. “Our approach shows that it is possible to separate the bad from the good, which has been a major hurdle in AML therapy,” Dotti said. The researchers believe further refinement could lead to clinical trials and eventually provide a safer option for patients who currently have limited choices.
This development aligns with broader efforts in the biotech industry to create advanced cancer therapies. Companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are also focused on next-generation immunotherapies. While the UNC work is preclinical, it highlights the potential for engineered cell therapies to transform AML treatment.
The implications of this research extend beyond AML. If successful in humans, the technology could be adapted for other blood cancers where healthy tissue damage limits treatment options. The study also underscores the importance of targeting specific antigens to improve safety and efficacy.
For more information on the research, visit the journal Blood or follow updates from the University of North Carolina Lineberger Comprehensive Cancer Center.
